Clinical Practice
Pramipexole for Treatment-Resistant Depression: What PMHNPs Should Know
The PAX-D trial showed pramipexole reduced treatment-resistant depression symptoms by week 12. Here's what PMHNPs need to know about dosing, monitoring, and clinical use.